# Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

> **NCT07368673** · PHASE4 · COMPLETED · sponsor: **Dow University of Health Sciences** · enrollment: 120 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** ruxolitinib cream

## Key facts

- **NCT ID:** NCT07368673
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-06
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-01-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07368673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07368673, "Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07368673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*